Boston Institute of Biotechnology
Boston Institute Of Biotechnology (BIB) is a full-service CDMO offering cGMP and non-GMP biologics, gene therapy, and cell therapy services. With extensive experience and innovative systems like PanFlex-Engineering, BIB provides comprehensive solutions from research to commercial manufacturing, including the world's first ultra-large bioreactor with a 30,000L capacity. Their mission is to provide high-quality, affordable medicines through trusted partnerships, leveraging advanced technologies and a highly experienced team to accelerate biopharmaceutical development and production.
Industries
Nr. of Employees
small (1-50)
Boston Institute of Biotechnology
Products
cGMP and non-GMP Manufacturing
Provides comprehensive manufacturing services for mammalian, microbial, gene therapy, and cell therapy processes, including both cGMP and non-GMP production.
Microbial Strain and Mammalian Cell Line Development
Offers development services for microbial strains and mammalian cell lines, capable of producing up to 10g/L of monoclonal antibodies.
Analytical and Formulation Development
Conducts analytical method development, assay qualification, and stability studies for biologics.
Process Development
Develops upstream and downstream processes for recombinant proteins, viral vaccines, and gene therapies using microbial or cell cultures.
Gene Therapy Services
Provides AAV-focused technology, including design, expression, purification, and analytical testing for gene therapy vectors.
Blue Whale Program
A manufacturing solution that reduces construction time and cost by 50%, addressing engineering and technology challenges.
cGMP and non-GMP Manufacturing
Provides comprehensive manufacturing services for mammalian, microbial, gene therapy, and cell therapy processes, including both cGMP and non-GMP production.
Microbial Strain and Mammalian Cell Line Development
Offers development services for microbial strains and mammalian cell lines, capable of producing up to 10g/L of monoclonal antibodies.
Analytical and Formulation Development
Conducts analytical method development, assay qualification, and stability studies for biologics.
Process Development
Develops upstream and downstream processes for recombinant proteins, viral vaccines, and gene therapies using microbial or cell cultures.
Gene Therapy Services
Provides AAV-focused technology, including design, expression, purification, and analytical testing for gene therapy vectors.
Blue Whale Program
A manufacturing solution that reduces construction time and cost by 50%, addressing engineering and technology challenges.
Services
Engineering and development of mammalian and microbial production cell lines and strains for therapeutic proteins and other biologics.
Process design and optimization for recombinant proteins, vaccines, and gene therapies covering fermentation/bioreactor processes and downstream purification.
Analytical method development, assay qualification and transfer, sample analysis, forced degradation and structure studies, and formulation development.
Design and execution of process characterization using DoE and QbD principles, including scale‑down modeling and parallel small‑scale platforms.
Commercial cGMP drug substance and drug product manufacturing across mammalian, microbial and gene therapy platforms, including fill & finish and non‑GMP/tox production support.
Integrated services for plasmid DNA and viral vector production, purification workflows, and quantitative vector analytics.
Engineering and development of mammalian and microbial production cell lines and strains for therapeutic proteins and other biologics.
Process design and optimization for recombinant proteins, vaccines, and gene therapies covering fermentation/bioreactor processes and downstream purification.
Analytical method development, assay qualification and transfer, sample analysis, forced degradation and structure studies, and formulation development.
Design and execution of process characterization using DoE and QbD principles, including scale‑down modeling and parallel small‑scale platforms.
Commercial cGMP drug substance and drug product manufacturing across mammalian, microbial and gene therapy platforms, including fill & finish and non‑GMP/tox production support.
Integrated services for plasmid DNA and viral vector production, purification workflows, and quantitative vector analytics.
Expertise Areas
- Cell line development
- Microbial strain development
- Upstream fermentation and scale‑up
- Downstream purification and filtration
Key Technologies
- Mammalian cell culture (high‑producing host cell lines)
- Microbial fermentation (E. coli, Pichia pastoris and similar hosts)
- Stirred‑tank bioreactors up to 30,000 L
- High‑cell density fermentation
News & Updates
Introduction of BIB's innovative platform integrating cell line development, process optimization, and manufacturing technologies.
Recognition of BIB's groundbreaking contributions including the world's first 30,000L bioreactor.
Importance of QC in ensuring safety and efficacy of biologics.
Strategic importance of collaborations in biopharmaceutical development.
Industry efforts towards environmental sustainability.
Key trends shaping the pharmaceutical landscape in 2024.
Introduction of BIB's innovative platform integrating cell line development, process optimization, and manufacturing technologies.
Recognition of BIB's groundbreaking contributions including the world's first 30,000L bioreactor.
Importance of QC in ensuring safety and efficacy of biologics.
Strategic importance of collaborations in biopharmaceutical development.
Industry efforts towards environmental sustainability.
Key trends shaping the pharmaceutical landscape in 2024.